Abstract
CFTR modulatory treatments have resulted in decrease in the frequency of pulmonary exacerbations, increase in quality of life and prolongation of lifespan in CF patients. However, since these drugs are not covered by health insurance in Turkey, eligible patients may sometimes have access to the therapy through lawsuits. In this study, we aimed to determine the eligibility of patients in our country for the modulators.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
